mRNA vaccine cuts melanoma death and recurrence by 42%
Original source
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Ars Technica →Intismeran is a personalized mRNA vaccine that encodes tumor-specific mutations found in a patient’s cancer cells but not their healthy tissue. Researchers sequence each patient’s tumor, identify cancer-exclusive mutations, and synthesize an mRNA sequence targeting those variants to focus immune response on malignant cells.
In a Phase 3 melanoma trial, patients treated with intismeran plus Keytruda showed a 42% reduction in recurrence or death risk compared to Keytruda-placebo controls within two years. Eighty-two percent of the combination group remained recurrence-free versus 70% of controls. For distant metastasis, the vaccine achieved a 38% risk reduction, with 88.5% metastasis-free versus 80% in controls.
The results fall short of an earlier Phase 2 trial showing 49% and 59% reductions in recurrence and metastasis risks respectively, but still represent a substantial clinical gain over existing immunotherapy alone. The individualized approach sets a new benchmark for melanoma adjuvant treatment.
Read the full article
Continue reading at Ars Technica →This is an AI-generated summary. Read the original for the full story.